A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Inclusion Criteria:

• Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medicationintake according to the judgement of the Investigator

• In the opinion of the Investigator, the study participant is expected to benefitfrom participation in this extension study

• Study participant completed AS0010 (NCT03928704) or AS0011 (NCT03928743)

Exclusion Criteria:

• Female study participants who plan to become pregnant during the study or within 20weeks following final dose of Investigational Medicinal Product (IMP). Male studyparticipants who are planning a partner pregnancy during the study or within 20weeks following the final dose

• Study participants who meet any withdrawal criteria in AS0010 or AS0011. For anystudy participant with an ongoing serious adverse event (SAE), or a history ofserious infections (including hospitalizations) in the feeder study, the MedicalMonitor must be consulted prior to the study participant's entry into AS0014

• Study participant has a positive or indeterminate interferon gamma release assay (IGRA) in AS0010 or AS0011, unless appropriately evaluated and treated